These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36726663)

  • 21. Prognostic factors in myelodysplastic syndromes.
    Triantafyllidis I; Ciobanu A; Stanca O; Lupu AR
    Maedica (Bucur); 2012 Dec; 7(4):295-302. PubMed ID: 23483702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myelodysplastic syndromes: clinicopathologic features, pathobiology, and molecular pathogenesis.
    Nishino HT; Chang CC
    Arch Pathol Lab Med; 2005 Oct; 129(10):1299-310. PubMed ID: 16196520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification].
    Schmitt-Graeff AH; Müller MJ; Fisch P
    Pathologe; 2013 Feb; 34(1):45-55. PubMed ID: 23322304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diagnosis and prognosis in myelodysplastic syndromes. The impact of cytogenetics].
    Mecucci C
    Recenti Prog Med; 2014 Mar; 105(3):110-4. PubMed ID: 24675452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
    Steensma DP
    Best Pract Res Clin Haematol; 2021 Dec; 34(4):101327. PubMed ID: 34865699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDS-type molecular findings compared to CCUS without dysplasia.
    Jajosky AN; Sadri N; Meyerson HJ; Oduro KA; Kelkar A; Fitzgerald B; Tomlinson B; Moore EM; Beck RC
    Eur J Haematol; 2021 Apr; 106(4):500-507. PubMed ID: 33386622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
    Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
    Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nuclear translocation of PKC-α is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs).
    Poli A; Ratti S; Finelli C; Mongiorgi S; Clissa C; Lonetti A; Cappellini A; Catozzi A; Barraco M; Suh PG; Manzoli L; McCubrey JA; Cocco L; Follo MY
    FASEB J; 2018 Feb; 32(2):681-692. PubMed ID: 28970249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients.
    Patnaik MM; Lasho TL; Finke CM; Knudson RA; Ketterling RP; Chen D; Hoyer JD; Hanson CA; Tefferi A
    Am J Hematol; 2011 May; 86(5):393-8. PubMed ID: 21523797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An update on the treatment of myelodysplastic syndromes.
    Kurtin SE; Demakos EP
    Clin J Oncol Nurs; 2010 Jun; 14(3):E29-44. PubMed ID: 20529786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies for biology- and molecular-based treatment of myelodysplastic syndromes.
    Lindberg EH
    Curr Drug Targets; 2005 Sep; 6(6):713-25. PubMed ID: 16178803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytogenetic aspects of adult primary myelodysplastic syndromes: clinical implications.
    Panani AD; Roussos C
    Cancer Lett; 2006 Apr; 235(2):177-90. PubMed ID: 15935553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malignant hematopoietic cell lines: in vitro models for the study of myelodysplastic syndromes.
    Drexler HG
    Leuk Res; 2000 Feb; 24(2):109-15. PubMed ID: 10654445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcriptome analysis of CD34+ cells from myelodysplastic syndrome patients.
    Ou R; Huang J; Shen H; Liu Z; Zhu Y; Zhong Q; Zheng L; Yao M; She Y; Zhou S; Chen R; Li C; Zhang Q; Liu S
    Leuk Res; 2017 Nov; 62():40-50. PubMed ID: 28982058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).
    Geyer JT; Verma S; Mathew S; Wang YL; Racchumi J; Espinal-Witter R; Subramaniyam S; Knowles DM; Orazi A
    Hum Pathol; 2013 Mar; 44(3):346-56. PubMed ID: 22995330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis, classification, and cytogenetics of myelodysplastic syndromes.
    Vallespí T; Imbert M; Mecucci C; Preudhomme C; Fenaux P
    Haematologica; 1998 Mar; 83(3):258-75. PubMed ID: 9573680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosis.
    Rauw J; Wells RA; Chesney A; Reis M; Zhang L; Buckstein R
    Leuk Res; 2011 Oct; 35(10):1335-8. PubMed ID: 21704372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
    Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
    Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Myelodysplastic syndromes--an overview for the practitioner].
    Solenthaler M; Tobler A
    Ther Umsch; 2004 Feb; 61(2):117-24. PubMed ID: 15018394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.